Apr 26, 2022 | Ad-hoc, CMC development, Featured news, News, Oligonucleotides
Strategic collaboration with Lilly to develop innovative and efficient processing solutions for the manufacture of oligonucleotide-based drug substances. The annual order volume has the potential to achieve around CHF 100 million, depending on Bachem reaching...
